Skip to main content

Advertisement

Table 8 Results from the cost-utility analysis

From: Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants

  Most effective VS least effective DMP* Incremental costs Incremental QALYs Mean ICER % of 5000 simulated ICERs per quadrant in the CE plane
      NW NE SW SE
Health care perspective         
CVR-primary# 7 VS 4 −534 0.003 −178,539 1 3 41 56
(297) (0.021)
CVR-secondary$ 1 VS 3 −671 0.012 −56,809 6 21 15 58
(976) (0.015)
CVR-both 2 VS 8 −721 0.005 −148,480 2 2 35 61
(416) (0.016)
COPD 1 VS 4 1,716 0.009 185,747 33 46 11 10
(2,000) (0.053)
DMII 1 VS 3 −677 0.013 −50,234 1 3 14 82
(398) (0.013)
Societal perspective         
CVR-primary# 7 VS 4 −1,131 0.003 −377,991 5 12 37 46
(1,334) (0.021)
CVR-secondary$ 1 VS 3 −153 0.012 −12,929 10 36 11 43
(1,225) (0.015)
CVR-both 2 VS 8 −604 0.005 −124,457 6 8 31 55
(554) (0.016)
COPD 1 VS 4 2,054 0.009 −222,314 34 47 11 9
(2,371) (0.053)
DMII 1 VS 3 −1,735 0.013 −128,790 1 2 14 83
(1,084) (0.013)
  1. *most effective is defined based on the highest incremental QALY and the reverse; #primary prevention for CVD; $secondary prevention for CVD; ICER: incremental cost-effectiveness ratio; CE: cost-effective(ness); best is defined as most effective based on QALYs and worse as the least effective based on the same measurement; the numbers correspond to the DMP numbers in Table 4.